Clinical Trial
Published on 12 Sep 2023
Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial
in Blood Cancer
![Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial](https://www.frontiersin.org/files/myhome article library/1244494/1244494_Thumb_400.jpg)
- 974 views
Clinical Trial
Published on 12 Sep 2023
in Blood Cancer
Original Research
Published on 25 Aug 2023
in Immunobiology and Immunotherapy
Brief Research Report
Published on 14 Aug 2023
in Red Cells, Iron and Erythropoiesis
Review
Published on 10 Aug 2023
in Immunobiology and Immunotherapy
Original Research
Published on 04 Aug 2023
in Red Cells, Iron and Erythropoiesis
Review
Published on 03 Aug 2023
in Immunobiology and Immunotherapy
Systematic Review
Published on 03 Aug 2023
in Hematopoiesis and Stem Cells
Original Research
Published on 29 Jun 2023
in Red Cells, Iron and Erythropoiesis
Original Research
Published on 26 Jun 2023
in Blood Cancer
Original Research
Published on 20 Jun 2023
in Blood Cancer
Review
Published on 20 Jun 2023
in Red Cells, Iron and Erythropoiesis
Case Report
Published on 30 May 2023
in Blood Cancer
Case Report
Published on 15 May 2023
in Immunobiology and Immunotherapy
Original Research
Published on 10 May 2023
in Immunobiology and Immunotherapy
Mini Review
Published on 03 May 2023
in Red Cells, Iron and Erythropoiesis
Original Research
Published on 25 Apr 2023
in Red Cells, Iron and Erythropoiesis